Kidney Week

Abstract: SA-PO0809

First Long-Term Real-World Evidence of Sparsentan Efficacy in Patients with IgAN Treated with SGLT2 Inhibitors

Session Information

• Glomerular Management: Real-World Lessons and Emerging Therapies
  November 08, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Schanz, Moritz, Robert-Bosch-Krankenhaus GmbH, Stuttgart, BW, Germany

Moritz Schanz, DrMed, MBA

• Seikrit, Claudia, Universitatsklinikum Aachen, Aachen, NRW, Germany

Claudia Seikrit, DrMed

• Hohenstein, Bernd, Nephrological Center Villingen-Schwenningen, Villingen-Schwenningen, Germany

Bernd Hohenstein, MD, FASN

• Meyer, Aline Katharina, MVZ Saarpfalz GmbH, Saarbrücken, Germany

Aline Katharina Meyer, DrMed

• Kraft, Leonie, Robert-Bosch-Krankenhaus GmbH, Stuttgart, BW, Germany

Leonie Kraft, MD, DrMed

• Schricker, Severin, Robert-Bosch-Krankenhaus GmbH, Stuttgart, BW, Germany

Severin Schricker, MD, DrMed

• Schwab, Andrea, Robert-Bosch-Krankenhaus GmbH, Stuttgart, BW, Germany

Andrea Schwab

• Oberacker, Tina, Doktor Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Stuttgart, BW, Germany

Tina Oberacker

• Latus, Joerg, Robert-Bosch-Krankenhaus GmbH, Stuttgart, BW, Germany

Joerg Latus, MD

Background

Sparsentan has emerged as a promising therapeutic option for IgA nephropathy. However, data on its effectiveness in real-world settings, particularly in combination with SGLT2 inhibitors remain limited. In our previously published real-world cohort (n=23), we demonstrated a significant reduction in proteinuria with concurrent SGLT2 inhibitor treatment. In this analysis, we present a subset of the Initial cohort that already has follow-up data available.

Methods

For our analysis, n=12 patients were identified with available follow-up data beyond the 6-month follow-up. Patients were stable under maximum tolerated RAAS and SGLT2 inhibitor therapy with an eGFR >30 ml/min/1.73 m² and a urine protein-creatinine ratio (UPCR) >0.75 g/gCreatinine.

Results

Of the twelve patients, at baseline median (IQR) eGFR (CKD-EPI) was 49 mL/min/1.73 m² (35-81) and median (IQR) UPCR was 1.29 g/g (0.89-1.80). In our extended follow-up, the UPCR remained significantly decreased (p=0.03) to a median of 0.45 g/g (IQR: 0.30-2.12) in the 10-month follow-up time (Figure 1), corresponding to a relative reduction of 65%. Remission rates increased with follow-up: More than two third (67%) achieved complete remission, 25% partial remission, while 8% showed no remission.

Conclusion

In the extended follow-up of our real-world data subset we could confirm initial findings that sparsentan offers a significant and sustained antiproteinuric effect even in patients already receiving SGLT2 inhibitors.

Course of proteinuria (UPCR) under therapy with sparsentan.

Funding

• Private Foundation Support

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.20254ws0zdx4